Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021)
Scholar Rock Holding (SRRK) recorded quarterly Total Non-Current Liabilities of $115.4 million in Q2 2021, down 3.87% quarter-over-quarter from $120.0 million in Q1 2021.
Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $115.4 million for Q2 2021.
- In Q2 2021, Total Non-Current Liabilities changed N/A year-over-year to $115.4 million; the TTM figure through Jun 2021 stood at $115.4 million (changed N/A YoY), while the FY2020 annual figure was $127.5 million, up 52.78% from the prior year.
- Total Non-Current Liabilities was $115.4 million for Q2 2021 at Scholar Rock Holding, down from $120.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $127.5 million in Q4 2020 to a low of $5.9 million in Q4 2017.
- Historically, Total Non-Current Liabilities has averaged $90.5 million across 4 years, with a median of $115.4 million in 2021.
- Biggest YoY gain for Total Non-Current Liabilities was 52.78% in 2020; the steepest drop was 52.78% in 2020.
- A 4-year view of Total Non-Current Liabilities shows it stood at $5.9 million in 2017, then soared by 1317.16% to $83.5 million in 2019, then jumped by 52.78% to $127.5 million in 2020, then fell by 9.52% to $115.4 million in 2021.
- The last three Total Non-Current Liabilities figures came in at $115.4 million (Q2 2021), $120.0 million (Q1 2021), and $127.5 million (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 115.39 Mn |
| Mar 31, 2021 | 120.04 Mn |
| Dec 31, 2020 | 127.53 Mn |
| Dec 31, 2019 | 83.47 Mn |
| Dec 31, 2017 | 5.89 Mn |